Disclosures This trial is supported by Eli Lilly and Company which supplies the study drug abemaciclib and Kom Op Tegen Kanker (Stand Up Against Cancer) which provides a grant.

#140 SURVEILLANCE OF CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 WITH DUAL P16/KI-67 IMMUNOCYTOCHEMISTRY STAINING. TRIAL PROTOCOL AND PRELIMINARY REPORT

Kimon Chatzistamatiou*, Vasilios Theodoulidis, Dimitrios Zouzoulas, Panagiotis Tzitzis, Anastasia Saitouva, Ililana Sofianou, Eleni Mpiili, Themistoklis Mikos, Grigorios Grimbizis, Dimitrios Tsolakidis. Aristotle University of Thessaloniki, Thessaloniki, Greece

10.1136/ijgc-2023-ESGO.870

Introduction/Background Cervical intraepithelial neoplasia (CIN) grade 2 is considered a high-grade squamous intraepithelial lesion requiring surgical treatment. Excisional cervical procedures, though, have been linked to an increased risk of preterm birth in subsequent pregnancies. Therefore, and given the fact that the vast majority of CIN2 cases will regress, there is a tendency to avoid surgical treatment for women who wish fertility preservation. The aim of the CIN2DIN study is to determine the diagnostic accuracy of P16/Ki-67 immunocytochemistry (ICC) for the timely detection of CIN3 +, among women with untreated CIN2, compared to colposcopy.

Methodology According to the study design, women with biopsy confirmed CIN2, after written informed consent, will be subjected to cervicovaginal sampling for p16/Ki-67 ICC (CINtec PLUS, Roche laboratories AG, Mannheim, Germany), cytology and high-risk Human Papillomavirus (hrHPV) testing (cobas® HPV Test, Roche Molecular Systems, Pleasanton, CA, USA) (t=0). After six months (t=1), participants will be subjected to colposcopy, and, cervicovaginal sampling for cytology and p16/Ki-67 ICC. After 12 months (t=2) participants will be subjected to colposcopy, and, to cervicovaginal sampling for hrHPV testing, cytology and p16/Ki-67 ICC. Participants will be also examined after 18 and 24 months (t=3, t=4, respectively). Examinations at t=3 and t=4 will be similar to t=1, and t=2 respectively. All women after visit t=4 exit the study and are referred to treatment according to the local guidelines.

Results To date 5 women with biopsy proven CIN2 have been recruited. Those women have been subjected to pap test, hrHPV testing, and p16/Ki-67 ICC.

Conclusion The CIN2DIN study is original and innovative. So far, no studies have been conducted on the value of P16/Ki-67 ICC for CIN2 surveillance. If the study identifies high correlation of P16/Ki-67 ICC to colposcopy, larger studies could be designed to investigate longer-term reassurance for the surveillance of women with untreated CIN2 without colposcopy.

Disclosures The authors have nothing to disclose.

#145 INTERNATIONAL VARIATIONS IN POST-OPERATIVE MORBIDITY AND MORTALITY FOLLOWING GYNAECOLOGICAL ONCOLOGY SURGERY (GO SOAR1)

1Faiza Gaba*, 2Karen Ash, 3Oleg Blyuss, 4Nicolo Bizzarri, 5Paul Kamfwa, 6Allison Saiz, 7Shantini Paranjothy, 8David Cibula. 1The Royal London Hospital, London, UK; 2University of Aberdeen, Aberdeen, UK; 3Aberdeen Royal Infirmary, Aberdeen, UK; 4Queen Mary University Of London, London, UK; 5Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy; 6Cancer Diseases Hospital, Lusaka, Zambia; 7Northwestern University, Chicago, USA; 8Charles University and General University Hospital, Prague, Czech Republic

10.1136/ijgc-2023-ESGO.871

Introduction/Background Gynaecological malignancies affect women in low and middle income countries (LMICs) at disproportionately higher rates compared with high income countries (HICs), but little is known about global variations in access, quality and outcomes in gynaecological oncology surgery between LMIC and HIC settings.

Methodology Multicentre, international prospective cohort-study of women undergoing surgery for primary ovary/uterus/ cervix/vulva/vagina/gestational trophoblastic malignancies (NCT04379861). Multilevel logistic-regression determined relationships within three-level nested models of patients within hospitals/countries.

Results We enrolled 1820 patients from 73 hospitals in 27 countries (1078 (59.2%) high income countries, 453 (24.9%) upper middle income countries, 174 (9.6%) lower middle income countries, 115 (6.3%) low income countries). Mean follow-up was 58.7 and 55.7 days from date of surgery in LMICs/HICs respectively. Overall-morbidity (Clavien-Dindo IV) for all tumour-groups was 34.7% (233/672) and 33.5% (338/1009), whilst mortality 2.1% (14/672) versus 1% (10/1009) for LMICs/HICs respectively. Minor-morbidity (Clavien-Dindo I-II) for all tumour-groups was 26.5% (267/1009), whilst major-morbidity (Clavien-Dindo III-V) 8.2% (55/672) and 7% (71/1009) for LMICs/HICs respectively. Higher minor-morbidity was associated with previous laparoscopic surgery (OR=1.435, 95%CI=1.046–1.966, p=0.025), COVID-19 positive status (OR=5.025, 95%CI=1.262–20.008, p=0.022), pre-operative mechanical bowel preparation (OR=1.474, 95%CI=1.054–2.061, p=0.023), longer surgeries (OR=1.253, 95%CI=1.066–1.472, p=0.006), greater blood loss (OR=1.274, 95%CI=1.081–1.502, p=0.004), and occurrence of intra-operative complication (OR=2.030, 95%CI=1.498–3.241, p<0.001). Minimal-access surgery was protective against minor-morbidity (OR=0.522, 95%CI=0.371–0.735, p=0.001). Higher major-morbidity was associated with longer surgeries (OR=1.37, 95%CI=1.128–1.664, p=0.002), greater blood loss (OR=1.398, 95%CI=1.175–1.664, p=0.001), and seniority of lead-surgeon with junior surgeons three times more likely to have a major-

Int J Gynecol Cancer 2023;33(Suppl 3):A1–A453
complication (OR=2.982, 95%CI=1.509–5.894, p=0.002). 50% versus 25% of all surgeries were performed by junior surgeons in LMICs/HICs respectively.

Conclusion LMICs were associated with greater post-operative major-morbidity. Capacity to rescue patients from surgical complications is a tangible opportunity for meaningful intervention.

Disclosures None.

#172 STREAM-I/AGO-OP.11/ENGOT-EN22: EVALUATION OF PREOPERATIVE CLINICAL AND TRANSLATIONAL SELECTION CRITERIA FOR CYTOREDUCTIVE SURGERY IN ENDOMETRIAL CANCER – STEP 1 OF THE STREAM (SURGICAL TREATMENT IN ADVANCED AND RECURRENT ENDOMETRIAL CANCER MANAGEMENT) INITIATIVE

1Fabián Trifich*, 2Lorenzo Ceppi, 3Pierre-Emmanuel Colombo, 4Alexander Reuß, 5Dana Josephy, 6Joanna Kacperczyk-Bartnik, 7Zoia Rozanova, 8Aleksandra Strojna, 9Oleksandr Zub, 10Jalid Sehouli, 11Christian Marth, 12Sven Mahner, 13Phillip Harter, 14Christoph Grimm, 15Alexandra Wagner. 1AGO and Department of Obstetrics and Gynecology, LMU Munich LMU University Hospital, LMU Munich LMU University Hospital, LMU Munich, Munich, Germany; 10MvVG and Gynecology and Obstetrics Department, Grande Ospedale Metropolitano Niguarda, Milano, Italy; 11GEO and Department of Surgical Oncology, Montpellier Cancer Institute (ICM), Montpellier, France; 14AGO and Coordinating Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; 12ENGOT and Gynecology-Oncology Unit, Sheba Medical Center, Tel-Aviv, Israel, 16PGG and Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland; 15NOGGO-CTU and Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden; 10CEEGOS and Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen Mitte, Essen, Germany; 11CEEGOS and Clinical oncology and gynecology department, Chernivtsi medical center of modern oncology, Chernivtsi, Ukraine; 12NOGGO and Department of Gynecology with Center for Oncological Surgery, Charité Gynecological Cancer Center and European Competence Center for Ovarian Cancer, Berlin, Germany; 11AGO-Austria and Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria, 13AGO and Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen Mitte, Essen, Germany, 11AGO-Austria and Division of General Gynecology and Gynecologic Oncology, Gynecologic Cancer Unit, Medical University Vienna, Vienna, Austria

Introduction/Background Endometrial cancer (EC) is the most common gynecological cancer in Europe with approximately 20% of patients being diagnosed in advanced stage (FIGO III-IV). Until now, only few studies exist for cytoreductive surgery (CRS) in advanced stage reporting of complete cytoreduction in 18–75% cases. Evidence for EC from large multicenter analyses data is missing and the indication for CRS is widely based on individual and/or institutional decision algorithms.

Methodology STREAM-I/AGO-OP

11/ENGOT-en22 is a retrospective, non-interventional, multicenter study aiming to identify preoperative clinical and molecular selection criteria for CRS. Patients who underwent CRS for advanced or recurrent EC at participating centers between 01/2011 and 12/2020 will be included. Available tumor material from CRS will be collected for evaluation of molecular classification and translational research. A multiple logistic regression identifying predictive factors for complete resection at CRS will be established using a stepwise covariate selection in the full clinical dataset. Therefore, a sample size of 800 patients was calculated based on estimated complete resection rates and number of independent variables.

Results As a result of this analysis, STREAM-II is planned as a consecutive prospective, single-arm, non-interventional, multicenter trial validating the predictive score established within the present study. Following confirmation, STREAM-III is planned to be a randomized, multicenter phase III trial evaluating CRS in EC.

Conclusion STREAM-I represents the first step towards Level I evidence for CRS in EC by identifying patients who most likely benefit from a radical surgical approach. STREAM-I will provide information to develop consecutive trials prospectively evaluating the impact of CRS in EC (STREAM-II-III).

Disclosures No direct conflict of interest for this surgical trial exists. Further relation to companies have been disclosed and uploaded.

#205 ROSELLA (GOG-3073, ENGOT-OV72/MITO): A PHASE 3 STUDY OF RELACORILANT + NAB-PACLITAXEL VS. NAB-PACLITAXEL IN ADVANCED, PLATINUM-RESISTANT OVARIAN CANCER

1Domenica Lorusso*, 2Andrea Bagamieri, 3Erin Bishop, 4Arista Chudecka-Glaz, 5Alix Devaux, 6Laurence Gladieff, 7Mary E Gordinier, 8Jeae-Weon Kim, 9Jacob Korach, 10Michael E McComb, 11Lisa Mileshkin, 12Bradley J Monk, 13Shibani Nicum, 14Angélica Nogueira-Rodrigues, 15Ana Oarkin, 16David O’Malley, 17Mauro Orlando, 18Lyndah Dreiling, 19Iulia Cristina Tudor, 20Alexander B Olawuyi, 21Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy; 1National Institute of Oncology, Budapest, Hungary; 2Medical College of Wisconsin, Milwaukee, USA; 3Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland; 4Oncology Department of Grand Hospital of Clamart, Châlons, Belgium; 5Institut Claudius Regaud, IUCT Oncopole, Toulouse, France; 6Norton Cancer Institute, Louisville, USA; 7Department of Obstetrics and Gynecology, Seoul National University, Seoul, South Korea; 8Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel; 9Virginia Oncology Associates, Norfolk, USA; 10Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; 12University of Arizona College of Medicine, Creighton University School of Medicine, HonorHealth Research Institute, GOG-Foundation, GOG-Partners, Scottsdale, USA; 11University College London Cancer Institute, London, UK; 12Federal University of Minas Gerais, Dom Oncologia e Oncoclinicas – Brazil, Belo Horizonte, Brazil; 13Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain; 14The Ohio State University and the James Cancer Center, GOG, Columbus, USA; 15Instituto Alexander Fleming, Buenos Aires, Argentina; 16Corcept Therapeutics, Inc, Menlo Park, USA; 17Corcept Therapeutics, Inc, Menlo Park, USA; 18University of Pittsburgh, Pittsburgh, USA

Introduction/Background Single agent chemotherapy are commonly used in platinum-resistant ovarian cancer, but outcomes are generally poor. Cortisol, which acts by binding to the glucocorticoid receptor (GR), can suppress apoptotic pathways used by cytotoxic agents. The GR is abundantly expressed in ovarian tumours and high GR expression is associated with poor outcomes. Data indicate that the selective GR modulator relacorilant can reverse cortisol’s anti-apoptotic effects, thereby enhancing chemotherapy efficacy. In a phase 2 study in patients with recurrent, platinum-refractory or platinum-resistant ovarian cancer, intermittently dosed relacorilant + nab-paclitaxel showed clinically meaningful improvement in progression-free survival (PFS), duration of response (DoR), and a trend toward improved overall survival (OS) without increased side effect burden compared to nab-paclitaxel monotherapy. This phase 3 study aims to confirm the findings of the phase 2 study in a larger patient population.

Methodology ROSELLA (GOG-3073, ENGOT-OV72/MITO, NCT05257408) is a randomised, phase 3, 2-arm, open-label study of relacorilant + nab-paclitaxel vs nab-paclitaxel